NVO - 3 Top Diabetes Stocks to Watch in November
There are plenty of exciting areas in the biotech world for investors to consider right now. One of the most promising niches is in the world of diabetes treatments, where a number of biotech companies are on the cusp of developing new solutions to the disease. There are 425 million adults worldwide living with the condition, and the figure is expected to increase to 629 million by 2045. As such, demand for potential diabetes treatments will continue to grow significantly in the years to come.
While there are a number of biotech companies focused on developing their own diabetes solutions, a few stand out from the competition. Provention Bio (NASDAQ: PRVB), Tandem Diabetes (NASDAQ: TNDM), and Eli Lilly (NYSE: LLY) are all companies working on promising diabetes solutions that investors should watch out for in November.
IMAGE SOURCE: GETTY IMAGES.